Clinical trials: Post-ischemic Stroke
Ischemic Stroke
Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial
A prospective, multi-center, randomized, sham-controlled, blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be conducted…
- Trial name
- E-FIT (NCT03010462)
- Testing
- Nexstim NBS guided active rTMS
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nexstim Ltd
Post-Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
- Trial name
- MILESTONE℠ (NCT02271217)
- Testing
- dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Where
- 74 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Acorda Therapeutics
Acute Ischemic Stroke
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
- Trial name
- PERFECT (NCT04531904)
- Testing
- EMBOVAC Aspiration Catheter
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 102 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Cerebrovascular Accident
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting.
- Trial name
- NCT00562588
- Testing
- Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in…
- Trial name
- NCT03258645
- Testing
- Dabigatran
- Where
- Sweden
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Trevo® Retriever Registry Post Market Surveillance
The purpose of the Trevo® Retriever Registry is to collect real world performance data of the Trevo Retriever which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic…
- Trial name
- NCT02040259
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 2,008 people
- Sponsor
- Stryker Neurovascular
Cryptogenic Stroke
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent…
- Trial name
- NCT00465270
- Testing
- AMPLATZER PFO Occluder, Standard of Care - Medical Management
- Where
- 69 sites in United States, Canada
- Volunteers
- 980 people
- Sponsor
- Abbott Medical Devices
Ischemic Stroke
Analysis of Revascularisation in Ischemic Stroke With EmboTrap
A.R.I.S.E. is a post approval observational study using standard care. The purpose of this study is to collect information about the ability of the EmboTrap device to remove blood clots from the brain, and the associated…
- Trial name
- ARISE (NCT02190552)
- Testing
- EmboTrap® Revascularization Device
- Where
- 5 sites in Denmark, Germany and 3 more
- Volunteers
- 40 people
- Sponsor
- Neuravi Limited
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Intracranial Atherosclerosis
Post Market Surveillance Study of the Wingspan Stent System
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
- Trial name
- WEAVE (NCT02034058)
- Testing
- Wingspan Stent System
- Where
- 26 sites in United States
- Volunteers
- 152 people
- Sponsor
- Stryker Neurovascular
Ischemic Stroke
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.
- Trial name
- NCT01605825
- Where
- 20 sites in United States
- Volunteers
- 83 people
- Sponsor
- Acorda Therapeutics
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Post-ischemic Stroke
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
- Trial name
- MILESTONE℠ (NCT02422940)
- Testing
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Where
- 66 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Acorda Therapeutics
Cerebral Infarction
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral…
- Trial name
- NCT00234065
- Testing
- Cilostazol, Aspirin
- Where
- Japan
- Volunteers
- 2,800 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.